# A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

> **NCT05108922** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 148 (actual)

## Conditions studied

- Mild Cognitive Impairment (MCI)
- Alzheimer Disease

## Interventions

- **DRUG:** Donanemab
- **DRUG:** Aducanumab

## Key facts

- **NCT ID:** NCT05108922
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-16
- **Primary completion:** 2022-09-09
- **Final completion:** 2023-09-19
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2024-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05108922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05108922, "A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05108922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*